WO1986004807A1 - Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments - Google Patents

Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments Download PDF

Info

Publication number
WO1986004807A1
WO1986004807A1 PCT/US1986/000288 US8600288W WO8604807A1 WO 1986004807 A1 WO1986004807 A1 WO 1986004807A1 US 8600288 W US8600288 W US 8600288W WO 8604807 A1 WO8604807 A1 WO 8604807A1
Authority
WO
WIPO (PCT)
Prior art keywords
glass fiber
reinforcement
fiber
cao
bioabsorbable
Prior art date
Application number
PCT/US1986/000288
Other languages
French (fr)
Inventor
George A. Graves, Jr.
Binod Kumar
Original Assignee
University Of Dayton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Dayton filed Critical University Of Dayton
Priority to JP61501190A priority Critical patent/JPH075335B2/en
Publication of WO1986004807A1 publication Critical patent/WO1986004807A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C13/00Fibre or filament compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61CDENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
    • A61C8/00Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
    • A61C8/0012Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/08Muscles; Tendons; Ligaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30965Reinforcing the prosthesis by embedding particles or fibres during moulding or dipping
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58Materials at least partially resorbable by the body
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C4/00Compositions for glass with special properties
    • C03C4/0007Compositions for glass with special properties for biologically-compatible glass
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00179Ceramics or ceramic-like structures
    • A61F2310/00293Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite
    • CCHEMISTRY; METALLURGY
    • C03GLASS; MINERAL OR SLAG WOOL
    • C03CCHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C2213/00Glass fibres or filaments
    • C03C2213/02Biodegradable glass fibres

Definitions

  • the present invention relates to biocompatible and bioabsorbable glass fibers for use in the area of medical implants, particularly orthopaedic and dental implants. More particularly, it relates to spun or drawn fibers containing primarily calcium oxide (CaO) and phos ⁇ phorous pentoxide ( ⁇ a ) which may be used as a rein ⁇ forcement for resorbable polymeric bone plates and artifi ⁇ cial ligaments.
  • CaO calcium oxide
  • ⁇ a phos ⁇ phorous pentoxide
  • the condition is allowed to persist, severe pain and/or refracturing of the bone can occur.
  • the underlying healed bone (callus) is usually not well organized. That is, the composite structure of the bone has not aligned itself such that it has maximum strength along the direc ⁇ tion (axis) of highest stress, which is the natural behavior of healthy mature bone. This can best take place if the stresses placed upon the bone are gradual, allowing the bone sufficient time to reorganize.
  • a similar problem exists in the attempted repair of torn, or partially torn ligaments or tendons.
  • Ligaments are composed of interwoven strands of collagen fibers very much like hemp rope. When these- fibers are broken, they will, if properly stabilized and the blood supply is adequate, repair themselves.
  • the collagen fibers do not realign themselves along lines of maximum stress if the stresses are being distributed over a permanently placed artificial support, such as metal wires. They remain in a disorganized mass, like scar tissue, with a much reduced strength when compared to normal ligamentous material. If the supporting artificial material is surgically removed, if that is even possible, there is great danger of the patient suddenly applying stress to the ligament that is too high for it to withstand and further damage will occur.
  • bioabsorbable ceramic materials may be used as medical implants. See, for example, U.S. patent 4,218,355 (assigned to the same assignee as the present invention) , which discloses use of an aluminum oxide/calcium oxide/phosphorous pentoxide porous ceramic material as a carrier for controlled release of proteins, polypeptide hormones and other substances.
  • this type of ceramic composition may be used as a bioabsorbable bone graft material. See also, U.S. Patent No. 4,155,124, which discloses a burnt ceramic bone implant, and the IADR Abstracts in the March 1982 issue of the Journal of Dental Research, various ones of which disclose work with biodegradable ceramic materials.
  • bioabsorbable synthetic polymers do not by themselves have sufficient structural strength to be used alone as an implant and the porous ceramic materials tend to be too rigid and brittle. Accordingly, the need exists for an improved biocompatible and bioabsorbable material for use in the area of orthopaedic and dental implants, and particularly a material which can be used to reinforce existing bioabsorbable synthetic polymers to form a com ⁇ posite suitable for that purpose.
  • the present invention meets that need by providing a reinforcement for bioabsorbable polymeric orthopaedic and dental implants, such a bone plates and artificial ligaments.
  • the reinforcement is a spun or drawn glass fiber having the required tensile strength and resorption properties.
  • the glass fiber is able to reinforce a polymer matrix as the resorbable polymer and the glass fiber is gradually being reduced in strength and elastic modulus (through slow, steady bioabsorption) , while allow ⁇ ing the bone or ligament to gradually reorganize and increase to normal strength and modulus.
  • the implant including tne glass fiber reinforcement, is completely consumed in the body causing no inflammatory, carcinogenic, or toxic reactions. Tnis is because of the bioabsoroable nature of the glass fiber reinforcement.
  • the spun or drawn glass fiber of the present invention is basically made up of a binary mixture of calcium oxide (CaO) and pnosphorous pentoxide (P 2 ° c ) » although, other ingredients sucn as calcium fluoride (CaF-) , water (H-O) , and other oxides containing cations such as magnesium, zinc, strontium, sodium, potas- sium, lithium and aluminum may also be incorporated in small amounts.
  • the pre ⁇ ferred Ca:P mole ratio is 0.25 to 0.33.
  • the glass comprises by weight 5-50% CaO, 50-95% P 2 0 5 , 0-5% CaF 2 , 0-5% H 2 0, and 0-10% XO, wherein X is a single magnesium, zinc or strontium ion or two sodium, potassium, lithium or aluminum ions and 0 is a single oxygen ion except when X is aluminum, in which case it is three oxygen ions. More preferably, the calcium oxide (CaO) is present by weight in the amount of 15-25%; the phosphorous pentoxide (P 2 0 5 ) is present by weight in the amount of 65-90%; and either calcium fluoride (CaF 2 ) or water (H.O) is present by weight in the amount of 0.1-4%.
  • CaO calcium oxide
  • P 2 0 5 phosphorous pentoxide
  • H.O water
  • the glass composition which is spun or drawn into the glass fiber reinforcement should obviously have good melting and fiber drawing characteristics. It should be capable of being drawn into fibers having a diameter between 1 to 100 microns, preferably 5 to 25 microns, and most preferably 8 to 15 microns, without crystallization during fiber drawing. Likewise, the drawn fibers should have a good tensile strength and modulus of elasticity.
  • the drawn fiber should be bioabsorbable, i.e., it should dissolve in vitro in a static solution of buffered saline in approximately 30 to 40 days, and should absorb in vivo, as implanted, slowly over six months to one year.
  • the glass fiber reinforcement of the present invention is able to gradually loose strength and safely absorb in the body as the strength of the bone, ligament, tendon or other body part is gradually and effectively increased.
  • the glass fiber of the present invention appropriately coated with a thin protective coating, may also be used by itself (and not necessarily as a reinforcement) as a bioabsorable suture, lashing, or other type of medical implant.
  • the glass composition used to produce the glass fiber reinforcement of the present invention preferably contains by weight 5-50%, most preferably 15-25%, calcium oxide (CaO) and 50-95%, most preferably 65-90%, phosphorous pentoxide (P 2 0 5 ) •
  • the preferred atomic ratio for calcium:phosphorous is about 0.25 to 0.33.
  • the glass composition is a binary mixture of calcium oxide and phosphorous pentoxide in the given ranges and having the preferred Ca:P mole ratio. However, usually other constituents are also present.
  • It may contain from 0-5% and preferably 0.1-4% by weight calcium fluoride (CaF 2 ) or water (H 2 0) or one or more of other oxides such as magnesium oxide (MgO) , zinc oxide (ZnO) , strontium oxide (SrO) , sodium oxide (Na 2 0) , potassium oxide (K 2 0) , or lithium oxide (Li 2 0) , or aluminum oxide (Al-,0-.) .
  • CaF 2 calcium fluoride
  • H 2 0 water
  • other oxides such as magnesium oxide (MgO) , zinc oxide (ZnO) , strontium oxide (SrO) , sodium oxide (Na 2 0) , potassium oxide (K 2 0) , or lithium oxide (Li 2 0) , or aluminum oxide (Al-,0-.) .
  • any added fluoride or oxide not result in development of undue crystallinity in the glass composition during fiber drawing. That is, the glass composition must be readily melted to a homo ⁇ geneous liquid having melt viscosity suitable for fiber drawing purposes.
  • these compositions have a melt viscosity of about 1000 to 10,000 poise at the drawing temperature.
  • the drawing temperature is preferably at least about 100°C above the liquidus temperature of the composition. It should be capable of being spun or drawn to a diameter of between 1 to 100 microns, preferably between 5 to 25 microns, and most preferably 8 to 15 microns using ordinary techniques. And it should have good tensile strength and modulus of elasticity so as to not be too rigid and brittle as are many ceramic materials.
  • the fiber In terms of tensile strength, the fiber should have a tensile strength ranging from 200 to 550 megapascals (MPa) and 30 to 200 thousand pounds per square incn (Ksi) , i.e., 30,000 to 80,000 psi.
  • the preferred range for Young's modulus is 2 x 10 to 7 x 10 psi.
  • the fiber should be bioabsorb ⁇ able so that upon implanting it will gradually resorb over a six-month to one-year period.
  • the chemical composition of the glass reinforcement fibers of the present invention is similar to that of fluoro and hydroxy apatite minerals which closely resemble the chemistry of bone minerals.
  • the chemical formulas for the fluoro and hydroxy apatites are a, Q Pg0 24 F 2 and a 1Q Pg0 24 (OH) 2 , respectively. If these formu ⁇ las are expressed as oxide and fluoride weight percent, the fluoro apatite would be expressed as CaO - 50.01%, CaF 2 - 7.74%, and P 2 0 5 - 42.25%.
  • the hydroxy apatite would be expressed as CaO - 54.91%, H 2 0 - 3.33%, and P o 5 - 41.75%.
  • These two minerals in the crystalline state can be chemically syntnesized in the laboratory.
  • These chemically synthesized apatites in powder or aggregate form are available in the aricet for bio-applications.
  • a material in the fibrous form is, however, being sought.
  • the fabrication of fibers from the two crystalline apatite minerals is difficult and to our knowledge has not before been used to produce a glass fiber reinforcement for use in the area of medical implants.
  • the present invention relates to the development of glass compositions for fiber making from the CaO-CaF 2 -P 2 0 5 and CaO-H 2 0-P 2 0 5 system.
  • Analytical grade powders of CaO, CaF 2 , and P 2 ° c were weighed to obtain a predetermined ratio and were then thoroughly mixed. The mixed batches were melted in a platinum crucible. The melting temperature and time depended upon the composition. The melting temperature ranged from 800°C to 1400°C, and the melting time varied from 15 minutes to 6 hours. Tne objective in all the melting experiments was to obtain a clear and homogeneous melt from which fibers could be drawn. After melting, the crucible was transferred to another furnace which was maintained at a lower temperature in order to maintain a proper viscosity for fiber drawing. The fibers were then drawn manually and the suitability of the various melts for fiber drawing was evaluated. The results are set forth in Table I.
  • compositions #1 #2 #3 #4
  • Composition #1 Highly refractory composition. Melting at 1400°C produced insignificant amount of liquid or glass phase.
  • Composition #2 Melted at 1400°C. A clear and homogeneous liquid was produced. However, fibers would not be drawn; the glass crystallized spontaneously during fiber drawing.
  • Composition #3 The composition melted to a homogeneous and clear liquid. Improved melt viscosity, but still crystallized during fiber drawing.
  • Composition #4 Melted at 900°C. Clear and homogeneous glass obtained. The composition exhibited excellent properties for fiber drawing.
  • composition #1 corresponds to the fluoro apatite mineral. This composi ⁇ tion is highly refractory and difficult to melt. By reducing CaO and increasing P 2 0 5 contents, the melt- ability was improved as in composition #2; however, it crystallized during fiber drawing. By further decreasing CaO and CaF 2 , and increasing P 2 0 5 as in compositions
  • composition #4 exhibited the most desirable melting and fiber drawing characteristics. Several hundred grams of glass and fibers were produced from composition #4 for use in bioco patibility evalua ⁇ tions.
  • Glass fibers drawn from composition f4 were drawn to diameters ranging from 0.0024-0.0045 inches. Some of these were tested for tensile strength and elasticity. The average tensile strength (five fibers tested) was 37,100 psi. The average Young's modulus was 2.4 x 10 psi. Some of the fibers drawn from composition #4 were placed in a static solution of buffered saline and were found to go into solution after approximately 40 days. Others of the fibers drawn from composition were implanted in rats and rabbits as single fibers and as fibers coated with a solution of polylactic acid. The results after 4, 12 and 24 week implant periods showed that the fibers slowly degraded and were consumed in the physiological environment, causing no inflammation or other untoward effects that could be ascertained by standard histological examination.
  • Table II As shown in Table II, ultimate tensile strength was determined from twenty-two mounted test fibers. A total of twenty-six fibers were mounted on 35 mm slide mounts using the technique discussed above. The diameter of each mounted fiber was determined by direct measurement on a micro-hardness tester. Specimens #4 and #26 were

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Manufacturing & Machinery (AREA)
  • Molecular Biology (AREA)
  • Ceramic Engineering (AREA)
  • Dentistry (AREA)
  • Composite Materials (AREA)
  • Materials For Medical Uses (AREA)
  • Glass Compositions (AREA)

Abstract

A spun or drawn glass fiber for use in the area of medical implants, and particularly as a reinforcement for bioabsorbable polymeric orthopedic and dental implants. The glass fiber is bioabsorbable and has sufficient tensile strength and elasticity to be used as a reinforcement. It is made up of 5-50% calcium oxide (CaO), 50-95% phosphorous pentoxide (P2O5), 0-5% calcium fluoride (CaF2), 0-5% water (H2O), and 0-10% XO wherein X is either a single magnesium, zinc or strontium ion or two sodium, potassium, lithium, or aluminum ions and when X is aluminum the O represents three oxygen ions.

Description

BIOABSORBABLE GLASS FIBERS FOR USE IN THE
REINFORCEMENT OF BIOABSORBABLE POLYMERS FOR
BONE FIXATION DEVICES AND ARTIFICIAL LIGAMENTS Background of the Invention The present invention relates to biocompatible and bioabsorbable glass fibers for use in the area of medical implants, particularly orthopaedic and dental implants. More particularly, it relates to spun or drawn fibers containing primarily calcium oxide (CaO) and phos¬ phorous pentoxide (~ a ) which may be used as a rein¬ forcement for resorbable polymeric bone plates and artifi¬ cial ligaments.
Many different materials have been used in the area of orthopaedic and dental implant devices. For example, various metals have been used as internal fixation . devices, the most common being compression plates, rods or pins. Today the vast majority of these devices are made up of stainless steel or titanium. They are used to hold fractured pieces of long bones in correct alignment and to minimize movement until a satisfactory union can take place by natural bone fracture healing processes.
This technique can provide quite satisfactory results; however, several problems can occur due to large differences in the modulus of elasticity of the bone and metal which usually results in the need for a second operation to remove the device. Also, for reasons not completely understood, some individuals do not tolerate the metal and the bone, or surrounding soft tissue, has an inflammatory response to the metal. The problem of differing elastic modulus between the bone and metal plate and the need for a second opera¬ tion can be, in some instances, directly related. In many cases, the person receiving the implant does not have the implant removed, either due to their own neglect or the surgeons. Even if a satisfactory bone union takes place, the large difference in the strength and modulus will actually result in a deterioration of the bone in tne vicinity of the metal plate. If the condition is allowed to persist, severe pain and/or refracturing of the bone can occur. Also, if the plate is removed, the underlying healed bone (callus) is usually not well organized. That is, the composite structure of the bone has not aligned itself such that it has maximum strength along the direc¬ tion (axis) of highest stress, which is the natural behavior of healthy mature bone. This can best take place if the stresses placed upon the bone are gradual, allowing the bone sufficient time to reorganize. A similar problem exists in the attempted repair of torn, or partially torn ligaments or tendons. Ligaments are composed of interwoven strands of collagen fibers very much like hemp rope. When these- fibers are broken, they will, if properly stabilized and the blood supply is adequate, repair themselves. In a manner similar to Done, the collagen fibers do not realign themselves along lines of maximum stress if the stresses are being distributed over a permanently placed artificial support, such as metal wires. They remain in a disorganized mass, like scar tissue, with a much reduced strength when compared to normal ligamentous material. If the supporting artificial material is surgically removed, if that is even possible, there is great danger of the patient suddenly applying stress to the ligament that is too high for it to withstand and further damage will occur.
For this reason, it has been proposed that a biocompatible composition be used in the repair or replace¬ ment of human body parts such as ligaments, tendons and bones. Thus, Alexander et al. in U.S. Patents No. 4,329,743 and 4,411,027 disclose using a composite of a bioabsorbable polymer (polylactic acid) on a substrate of a plurality of carbon fibers. See also U.S. patent 4,141,087, 4,140,678 and 4,052,988 which disclose various bioabsorbable synthetic polymers for use as permanent sutures, artificial ligaments and bone plates. However, while the polymer of Alexander et al. is bioabsorbable, the carbon fiber reinforcement is not. Since 30-60% of the bone plates and artificial ligaments of Alexander et al. are made up of the carbon fibers, the problem of bioincompatibility remains due to their being stiff and non-bioabsorbable.
It is also known that bioabsorbable ceramic materials may be used as medical implants. See, for example, U.S. patent 4,218,355 (assigned to the same assignee as the present invention) , which discloses use of an aluminum oxide/calcium oxide/phosphorous pentoxide porous ceramic material as a carrier for controlled release of proteins, polypeptide hormones and other substances.
It is also known that this type of ceramic composition may be used as a bioabsorbable bone graft material. See also, U.S. Patent No. 4,155,124, which discloses a burnt ceramic bone implant, and the IADR Abstracts in the March 1982 issue of the Journal of Dental Research, various ones of which disclose work with biodegradable ceramic materials.
Despite the recent efforts to develop a bio¬ absorbable composition or composite which may be used as an orthopaedic and dental implant, much work remains to be done. The bioabsorbable synthetic polymers do not by themselves have sufficient structural strength to be used alone as an implant and the porous ceramic materials tend to be too rigid and brittle. Accordingly, the need exists for an improved biocompatible and bioabsorbable material for use in the area of orthopaedic and dental implants, and particularly a material which can be used to reinforce existing bioabsorbable synthetic polymers to form a com¬ posite suitable for that purpose.
Summary of the Invention The present invention meets that need by providing a reinforcement for bioabsorbable polymeric orthopaedic and dental implants, such a bone plates and artificial ligaments. The reinforcement is a spun or drawn glass fiber having the required tensile strength and resorption properties. As such, the glass fiber is able to reinforce a polymer matrix as the resorbable polymer and the glass fiber is gradually being reduced in strength and elastic modulus (through slow, steady bioabsorption) , while allow¬ ing the bone or ligament to gradually reorganize and increase to normal strength and modulus. • After a reason¬ able period of time (approximately one year) , the implant, including tne glass fiber reinforcement, is completely consumed in the body causing no inflammatory, carcinogenic, or toxic reactions. Tnis is because of the bioabsoroable nature of the glass fiber reinforcement.
The spun or drawn glass fiber of the present invention is basically made up of a binary mixture of calcium oxide (CaO) and pnosphorous pentoxide (P2°c) » although, other ingredients sucn as calcium fluoride (CaF-) , water (H-O) , and other oxides containing cations such as magnesium, zinc, strontium, sodium, potas- sium, lithium and aluminum may also be incorporated in small amounts. In terms of the binary mixture, the pre¬ ferred Ca:P mole ratio is 0.25 to 0.33. Preferably, the glass comprises by weight 5-50% CaO, 50-95% P205, 0-5% CaF2, 0-5% H20, and 0-10% XO, wherein X is a single magnesium, zinc or strontium ion or two sodium, potassium, lithium or aluminum ions and 0 is a single oxygen ion except when X is aluminum, in which case it is three oxygen ions. More preferably, the calcium oxide (CaO) is present by weight in the amount of 15-25%; the phosphorous pentoxide (P205) is present by weight in the amount of 65-90%; and either calcium fluoride (CaF2) or water (H.O) is present by weight in the amount of 0.1-4%.
The glass composition which is spun or drawn into the glass fiber reinforcement should obviously have good melting and fiber drawing characteristics. It should be capable of being drawn into fibers having a diameter between 1 to 100 microns, preferably 5 to 25 microns, and most preferably 8 to 15 microns, without crystallization during fiber drawing. Likewise, the drawn fibers should have a good tensile strength and modulus of elasticity.
Finally, the drawn fiber should be bioabsorbable, i.e., it should dissolve in vitro in a static solution of buffered saline in approximately 30 to 40 days, and should absorb in vivo, as implanted, slowly over six months to one year. In this manner, the glass fiber reinforcement of the present invention is able to gradually loose strength and safely absorb in the body as the strength of the bone, ligament, tendon or other body part is gradually and effectively increased. The glass fiber of the present invention, appropriately coated with a thin protective coating, may also be used by itself (and not necessarily as a reinforcement) as a bioabsorable suture, lashing, or other type of medical implant.
Accordingly, it is an object of the present invention to provide a spun or drawn glass fiber which is bioabsorbable and useful in the area of medical implants, particularly orthopaedic and dental implants.
These and other objects of the invention will be apparent from the following description and the appended claims.
Detailed Description of the Preferred Embodiments The glass composition used to produce the glass fiber reinforcement of the present invention as mentioned, preferably contains by weight 5-50%, most preferably 15-25%, calcium oxide (CaO) and 50-95%, most preferably 65-90%, phosphorous pentoxide (P205) • The preferred atomic ratio for calcium:phosphorous is about 0.25 to 0.33. Thus, in its basic form, the glass composition is a binary mixture of calcium oxide and phosphorous pentoxide in the given ranges and having the preferred Ca:P mole ratio. However, usually other constituents are also present. It may contain from 0-5% and preferably 0.1-4% by weight calcium fluoride (CaF2) or water (H20) or one or more of other oxides such as magnesium oxide (MgO) , zinc oxide (ZnO) , strontium oxide (SrO) , sodium oxide (Na20) , potassium oxide (K20) , or lithium oxide (Li20) , or aluminum oxide (Al-,0-.) .
It is important, however, that any added fluoride or oxide not result in development of undue crystallinity in the glass composition during fiber drawing. That is, the glass composition must be readily melted to a homo¬ geneous liquid having melt viscosity suitable for fiber drawing purposes. Typically, these compositions have a melt viscosity of about 1000 to 10,000 poise at the drawing temperature. The drawing temperature is preferably at least about 100°C above the liquidus temperature of the composition. It should be capable of being spun or drawn to a diameter of between 1 to 100 microns, preferably between 5 to 25 microns, and most preferably 8 to 15 microns using ordinary techniques. And it should have good tensile strength and modulus of elasticity so as to not be too rigid and brittle as are many ceramic materials.
In terms of tensile strength, the fiber should have a tensile strength ranging from 200 to 550 megapascals (MPa) and 30 to 200 thousand pounds per square incn (Ksi) , i.e., 30,000 to 80,000 psi. The preferred range for Young's modulus is 2 x 10 to 7 x 10 psi.
Also as mentioned, the fiber should be bioabsorb¬ able so that upon implanting it will gradually resorb over a six-month to one-year period. A key to this is the fact that the chemical composition of the glass reinforcement fibers of the present invention is similar to that of fluoro and hydroxy apatite minerals which closely resemble the chemistry of bone minerals. The chemical formulas for the fluoro and hydroxy apatites are a,QPg024F2 and a1QPg024 (OH)2, respectively. If these formu¬ las are expressed as oxide and fluoride weight percent, the fluoro apatite would be expressed as CaO - 50.01%, CaF2 - 7.74%, and P205 - 42.25%. Similarly, the hydroxy apatite would be expressed as CaO - 54.91%, H20 - 3.33%, and P o5 - 41.75%. These two minerals in the crystalline state can be chemically syntnesized in the laboratory. These chemically synthesized apatites in powder or aggregate form are available in the aricet for bio-applications. For present purposes, a material in the fibrous form is, however, being sought. The fabrication of fibers from the two crystalline apatite minerals is difficult and to our knowledge has not before been used to produce a glass fiber reinforcement for use in the area of medical implants. However, if these two minerals can be produced in the vitreous or amorphous state and a desirable viscos¬ ity range is obtained, fibers could easily be drawn. The present invention relates to the development of glass compositions for fiber making from the CaO-CaF2-P205 and CaO-H20-P205 system.
Example I
Analytical grade powders of CaO, CaF2, and P2°c were weighed to obtain a predetermined ratio and were then thoroughly mixed. The mixed batches were melted in a platinum crucible. The melting temperature and time depended upon the composition. The melting temperature ranged from 800°C to 1400°C, and the melting time varied from 15 minutes to 6 hours. Tne objective in all the melting experiments was to obtain a clear and homogeneous melt from which fibers could be drawn. After melting, the crucible was transferred to another furnace which was maintained at a lower temperature in order to maintain a proper viscosity for fiber drawing. The fibers were then drawn manually and the suitability of the various melts for fiber drawing was evaluated. The results are set forth in Table I.
TABLE I
COMPOSITIONS IN WEIGHT PERCENT
Compositions: #1 #2 #3 #4
CaO 50.01 48.00 40.00 23.00
CaF2 7.74 7.75 6.00 0.00 P P22OO55 4 422..2255 44.25 54.00 77.00 -9-
Remarks:
Composition #1: Highly refractory composition. Melting at 1400°C produced insignificant amount of liquid or glass phase. Composition #2: Melted at 1400°C. A clear and homogeneous liquid was produced. However, fibers would not be drawn; the glass crystallized spontaneously during fiber drawing.
Composition #3: The composition melted to a homogeneous and clear liquid. Improved melt viscosity, but still crystallized during fiber drawing.
Composition #4: Melted at 900°C. Clear and homogeneous glass obtained. The composition exhibited excellent properties for fiber drawing.
As can be seen from Table I, composition #1 corresponds to the fluoro apatite mineral. This composi¬ tion is highly refractory and difficult to melt. By reducing CaO and increasing P205 contents, the melt- ability was improved as in composition #2; however, it crystallized during fiber drawing. By further decreasing CaO and CaF2, and increasing P205 as in compositions
#3 and #4, meltability as well as fiber drawing character¬ istics were improved. Composition #4 exhibited the most desirable melting and fiber drawing characteristics. Several hundred grams of glass and fibers were produced from composition #4 for use in bioco patibility evalua¬ tions.
Glass fibers drawn from composition f4 were drawn to diameters ranging from 0.0024-0.0045 inches. Some of these were tested for tensile strength and elasticity. The average tensile strength (five fibers tested) was 37,100 psi. The average Young's modulus was 2.4 x 10 psi. Some of the fibers drawn from composition #4 were placed in a static solution of buffered saline and were found to go into solution after approximately 40 days. Others of the fibers drawn from composition were implanted in rats and rabbits as single fibers and as fibers coated with a solution of polylactic acid. The results after 4, 12 and 24 week implant periods showed that the fibers slowly degraded and were consumed in the physiological environment, causing no inflammation or other untoward effects that could be ascertained by standard histological examination.
Example II
Eighty-five (85) grams of bulk glass was prepared from, by weight, 20% calcium oxide (CaO) , 77% phosphorous pentoxide (P Oς) , and 3% water (H20) . The entire 85 grams was drawn into a continuous fiber that ranged in diameter from 8 to 12 microns.
Static dissolution studies performed on some of the fibers showed them to be absorbable in vitro (in buffered saline) and others of fibers from the same batch were implanted (uncoated) in the back muscles of rabbits.
The histology indicated that these fioers dissolved in vivo and were consumed in approximately 6 months.
Others of tne fibers were tested for mechanical properties. The results of those studies are set forth in
Table II. As shown in Table II, ultimate tensile strength was determined from twenty-two mounted test fibers. A total of twenty-six fibers were mounted on 35 mm slide mounts using the technique discussed above. The diameter of each mounted fiber was determined by direct measurement on a micro-hardness tester. Specimens #4 and #26 were
Figure imgf000012_0001
-11-
observed to be twisted double fiber mounts while measuring fiber diameters and therefore were not tested. Specimen #1 was broken during the cutting and clipping of the slide mount immediately prior to testing. Specimen #24 failed in the wax at the slide mount and was deemed an invalid test. The results for the remaining test specimens are compiled in Table II.
TABLE II
GLASS FIBER TENSILE TEST RESULTS
SPECIMEN DIAMETER ULTIMATE TENSILE STRENGTH
NUMBER (microns) MPa ksi
2 12.3 362.4 52.6
3 11.2 402.3 58.3
5 14.1 317.9 46.1
6 13.6 357.9 51.9
7 12.0 376.4 54.6
8 13.1 414.9 60.2
9 12.4 320.9 46.5
10 12.6 360.3 52.3
11 13.6 393.8 42.6
12 11.6 339.7 49.3
13 12.5 372.5 54.0
14 12.8 301.9 43.8
15 10.8 463.7 67.2
16 11.1 _ 472.5 68.5
17 12.8 521.5 75.6
18 13.2 414.3 60.1
19 11.5 410.8 59.6
20 12.0 459.7 66.7
21 11.2 450.1 65.3
22 10.7 512.8 74.4
23 13.2 448.0 65.0
25 13.5 390.6 56.7
X 12.4 398.4 57.8 s 1.0 65.2 9.5 While the product herein described constitutes preferred embodiments of the invention, it is to be under¬ stood that the invention is not limited to this precise product, and that changes may be made therein without departing from the scope of the invention which is defined in the appended claims.
What is claimed is:

Claims

-13-
1. A spun or drawn glass fiber, which is bioabsorb- able and useful in the area of medical implants, comprising calcium oxide (CaO) and phosphj^ous pentoxide (P20-.) .
2. The glass fiber of claim 1 wherein said fiber has a diameter in the range of 1-100 microns.
3. The glass fiber of claim 2 wherein said fiber has a diameter in the range of 5-25 microns.
4. The glass fiber of claim 2 wherein said glass fiber comprises by weight:
CaO 5-50%
P205 50-95% CaF2 0-5%
H20 0-5%
XO 0-10% wherein X is selected from the group consisting of a single magnesium, zinc or strontium ion and two sodium, potassium, lithium or aluminum ions, and when X is aluminum O is three oxygen ions.
5. The glass fiber of claim 4 wherein said calcium oxide (CaO) is present by weignt in the amount of 15-25% and said phosphorous pentoxide (?205) is present by weight in the amount of 65-90%.
6. The glass fiber of claim 4 wherein said calcium fluoride (CaF2) is present by weight in the amount of 0.1-4%.
7. The glass fiber of claim 4 wherein said water (H20) is present by weight in the amount of 0.1-4%. -14-
8. The glass fiber of claim 1 wherein the Ca:P atomic ratio is about 0.25 to 0.33.
9. A reinforcement for a bioabsorbable polymeric orthopaedic or dental implant comprising a drawn or spun glass fiber made up of by weight of:
CaO 5-50% P205 50-95%
CaF2 0-5%
H20 0-5%
XO 0-10% wherein X is selected from the group consisting of a single magnesium, zinc or strontium ion and two sodium, potassium, lithium or aluminum ions, and when X is aluminum O is three oxygen ions.
10. The reinforcement of claim 9 wherein said fiber has a dimater in the range of 5 to 25 microns.
11. The reinforcement of claim 10 wherein said fiber has a diameter in the range of 8 to 15 microns.
12. The reinforcement of claim 11 wherein said fiber has a tensile strength of 30,000 to 200,000 psi and a Young's modulus of 2 x 10 to 7 x 10 psi.
13. The reinforcement of claim 12 wherein said glass fiber comprises by weight:
CaO 15-25%,
P20_ 65-90%, and H20 0.1-4%. -15-
14. The reinforcement of claim 9 wherein the Ca:P atomic ratio is 0.25 to 0.33.
15. The glass fiber of claim 1 wherein said fiber has a melt viscosity of 1000 to 10,000 poise at its drawing temperature.
PCT/US1986/000288 1985-02-19 1986-02-10 Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments WO1986004807A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP61501190A JPH075335B2 (en) 1985-02-19 1986-02-10 Bioabsorbable glass fibers used to reinforce bioabsorbable polymers for bone anchors and artificial ligaments

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US702,526 1985-02-19
US06/702,526 US4604097A (en) 1985-02-19 1985-02-19 Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments

Publications (1)

Publication Number Publication Date
WO1986004807A1 true WO1986004807A1 (en) 1986-08-28

Family

ID=24821567

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/000288 WO1986004807A1 (en) 1985-02-19 1986-02-10 Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments

Country Status (5)

Country Link
US (1) US4604097A (en)
EP (1) EP0211942A4 (en)
JP (1) JPH075335B2 (en)
AU (1) AU5518386A (en)
WO (1) WO1986004807A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268463A2 (en) * 1986-11-19 1988-05-25 The University Of Dayton Zinc based ceramics
EP0271236A1 (en) * 1986-11-25 1988-06-15 The University Of Dayton Controlled pore size ceramics particularly for orthopaedic and dental applications
EP0591696A1 (en) * 1992-10-09 1994-04-13 Nikon Corporation Bone grafting material
WO1998054104A1 (en) * 1997-05-31 1998-12-03 Giltech Limited Method of producing water-soluble glass fibres
US5928975A (en) * 1995-09-21 1999-07-27 The Morgan Crucible Company,Plc Saline soluble inorganic fibers
US5994247A (en) * 1992-01-17 1999-11-30 The Morgan Crucible Company Plc Saline soluble inorganic fibres
US5998315A (en) * 1994-08-02 1999-12-07 Morgan Crucible Company Plc Strontium aluminate inorganic fibers
WO2003059835A1 (en) 2002-01-04 2003-07-24 The Morgan Crucible Company Plc Saline soluble inorganic fibres
WO2008065363A1 (en) 2006-11-28 2008-06-05 The Morgan Crucible Company Plc Inorganic fibre compositions
EP2213634A1 (en) 2007-11-23 2010-08-04 The Morgan Crucible Company Plc Inorganic fibre compositions
US8163377B2 (en) 2005-11-10 2012-04-24 The Morgan Crucible Company Plc High temperature resistant fibres
US8899981B2 (en) 2005-08-30 2014-12-02 Zimmer Dental, Inc. Dental implant for a jaw with reduced bone volume and improved osseointegration features
US9095396B2 (en) 2008-07-02 2015-08-04 Zimmer Dental, Inc. Porous implant with non-porous threads
US9149345B2 (en) 2007-08-30 2015-10-06 Zimmer Dental, Inc. Multiple root implant

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820573A (en) * 1983-07-06 1989-04-11 Mitsubishi Mining And Cement Co., Ltd. Fiber glass mainly composed of calcium phosphate
FI81498C (en) * 1987-01-13 1990-11-12 Biocon Oy SURGICAL MATERIAL OCH INSTRUMENT.
US5192330A (en) * 1987-01-20 1993-03-09 Smith & Nephew Richards, Inc. Orthopedic device of biocompatible polymer with oriented fiber reinforcement
US4894012A (en) * 1987-11-16 1990-01-16 The University Of Connecticut Passive dental appliances of fiber-reinforced composites
US4902224A (en) * 1988-12-19 1990-02-20 Union Carbide Chemicals And Plastics Company Inc. Crystalline orthodontic bracket
US5215563A (en) * 1990-05-04 1993-06-01 Alfred University Process for preparing a durable glass composition
US5074916A (en) * 1990-05-18 1991-12-24 Geltech, Inc. Alkali-free bioactive sol-gel compositions
CA2060635A1 (en) * 1991-02-12 1992-08-13 Keith D'alessio Bioabsorbable medical implants
US5162267A (en) * 1991-09-27 1992-11-10 Smyth Milagros B Radio-opaque calcium phosphate glass
US5252523A (en) * 1991-10-09 1993-10-12 Corning Incorporated Bioabsorbable chlorophosphate glasses and bioabsorbable glass-polymer blends made therefrom
HU218828B (en) * 1992-01-17 2000-12-28 The Morgan Crucible Co. Plc. Saline soluble inorganic fibres
EP0642773B1 (en) * 1993-09-14 2003-05-28 Lanny L. Johnson Biological replacement ligament
US6371763B1 (en) * 1997-11-28 2002-04-16 Robert J. Sicurelli, Jr. Flexible post in a dental post and core system
US5721049A (en) * 1993-11-15 1998-02-24 Trustees Of The University Of Pennsylvania Composite materials using bone bioactive glass and ceramic fibers
US6121172A (en) * 1993-11-15 2000-09-19 The Trustees Of The University Of Pennsylvania Composite materials using bone bioactive glass and ceramic fibers
US5468544A (en) * 1993-11-15 1995-11-21 The Trustees Of The University Of Pennsylvania Composite materials using bone bioactive glass and ceramic fibers
US5769899A (en) * 1994-08-12 1998-06-23 Matrix Biotechnologies, Inc. Cartilage repair unit
US5874375A (en) * 1995-10-30 1999-02-23 Unifrax Corporation High temperature resistant glass fiber
US6030910A (en) * 1995-10-30 2000-02-29 Unifrax Corporation High temperature resistant glass fiber
EP0895511B1 (en) * 1996-04-24 2001-12-05 Owens Corning Glass compositions having high ki values and fibers therefrom
US6034014A (en) * 1997-08-04 2000-03-07 Owens Corning Fiberglas Technology, Inc. Glass fiber composition
CA2314963A1 (en) * 1998-01-06 1999-07-15 Bioamide, Inc. Bioabsorbable fibers and reinforced composites produced therefrom
GB9811661D0 (en) * 1998-06-01 1998-07-29 Giltech Ltd Compositions
ZA989387B (en) * 1998-08-13 1999-04-15 Unifrax Corp High temperature resistant glass fiber
FI110063B (en) * 1998-12-11 2002-11-29 Antti Yli-Urpo New bioactive product and its use
US6147135A (en) 1998-12-31 2000-11-14 Ethicon, Inc. Fabrication of biocompatible polymeric composites
US6383519B1 (en) 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
US6884427B1 (en) * 1999-02-08 2005-04-26 Aderans Research Institute, Inc. Filamentary means for introducing agents into tissue of a living host
GB9902976D0 (en) * 1999-02-11 1999-03-31 Giltech Ltd Composite
US6667049B2 (en) 1999-06-14 2003-12-23 Ethicon, Inc. Relic process for producing bioresorbable ceramic tissue scaffolds
US6458162B1 (en) * 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
US20040037871A1 (en) * 1999-10-20 2004-02-26 Healy David Michael Suture material
US6593394B1 (en) * 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
PL363113A1 (en) * 2000-03-27 2004-11-15 Schott Glas New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
AU2001261300A1 (en) * 2000-05-09 2001-11-20 Pearl Technology Holdings, Llc Biodegradable fiber optic
US20030164583A1 (en) * 2000-08-04 2003-09-04 Eaton Paul Nigel Bonded fibrous materials
WO2002015952A1 (en) * 2000-08-08 2002-02-28 Bioamide, Inc. Scaffolds for tissue engineered hair
US7005135B2 (en) * 2001-01-30 2006-02-28 Ethicon Inc. Glass scaffolds with controlled resorption rates and methods for making same
US20120330420A1 (en) * 2001-05-01 2012-12-27 Amedica Corporation Spinal fusion implants
DE10137010C1 (en) * 2001-07-28 2003-03-13 Aesculap Ag & Co Kg Medicinal implant system comprises an implant consisting of a composite material containing glass fibers, at least one of which is connected to a sender transmitting radiation into the implant
AU2003235668B2 (en) * 2002-01-10 2008-10-02 Unifrax Corporation High temperature resistant vitreous inorganic fiber
US20040068284A1 (en) * 2002-01-29 2004-04-08 Barrows Thomas H. Method for stimulating hair growth and kit for carrying out said method
US20050118236A1 (en) * 2002-12-03 2005-06-02 Gentis Inc. Bioactive, resorbable scaffolds for tissue engineering
US7468337B2 (en) * 2003-06-27 2008-12-23 Unifrax I Llc High temperature resistant vitreous inorganic fiber
AU2004252156B2 (en) * 2003-06-27 2009-03-12 Unifrax I Llc High temperature resistant vitreous inorganic fiber
US7854756B2 (en) * 2004-01-22 2010-12-21 Boston Scientific Scimed, Inc. Medical devices
US7597885B2 (en) * 2004-03-26 2009-10-06 Aderans Research Institute, Inc. Tissue engineered biomimetic hair follicle graft
WO2005105172A1 (en) 2004-04-20 2005-11-10 Genzyme Corporation Surgical mesh-like implant
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
AR050212A1 (en) * 2004-08-13 2006-10-04 Aderans Res Inst Inc ORGANOGENESIS FROM DISCELLED CELLS
US7875566B2 (en) * 2004-11-01 2011-01-25 The Morgan Crucible Company Plc Modification of alkaline earth silicate fibres
BRPI0613080B1 (en) * 2005-06-30 2017-02-21 Unifrax I Llc low shrinkage high temperature resistant inorganic fiber and article containing inorganic fiber
AR057628A1 (en) * 2005-11-22 2007-12-05 Aderans Res Inst Inc CAPITAL DIVERTS DERIVED FROM EXTRACTED HAIR
US20070148138A1 (en) * 2005-11-22 2007-06-28 Aderans Research Institute, Inc. Hair follicle graft from tissue engineered skin
US7651966B2 (en) * 2006-04-18 2010-01-26 Mo-Sci Corporation Alkaline resistant phosphate glasses and method of preparation and use thereof
EP2040765A2 (en) 2006-06-29 2009-04-01 Orthovita, INC. Bioactive bone graft substitute
WO2008067531A2 (en) * 2006-11-30 2008-06-05 Smith & Nephew, Inc. Fiber reinforced composite material
EP2142110B1 (en) 2006-12-26 2012-05-23 Solvay Specialty Polymers USA, LLC. Orthopedic tool made of a plastic material
US7985537B2 (en) * 2007-06-12 2011-07-26 Aderans Research Institute, Inc. Methods for determining the hair follicle inductive properties of a composition
JP2009120998A (en) * 2007-11-16 2009-06-04 Japan Fine Ceramics Center Inorganic fiber
US20110206828A1 (en) * 2009-07-10 2011-08-25 Bio2 Technologies, Inc. Devices and Methods for Tissue Engineering
KR101683328B1 (en) * 2009-07-10 2016-12-06 바이오2 테크놀로지스, 아이엔씨. Devices and methods for tissue engineering
US9775721B2 (en) 2009-07-10 2017-10-03 Bio2 Technologies, Inc. Resorbable interbody device
KR101223675B1 (en) 2009-11-27 2013-01-17 주식회사 케이씨씨 Saline soluble ceramic fiber composition
US20110151027A1 (en) * 2009-12-21 2011-06-23 Theodore D Clineff Strontium-doped calcium phosphate bone graft materials
KR101206365B1 (en) 2010-02-24 2012-11-29 주식회사 케이씨씨 A composition for preparing ceramic fiber and a biosoluble ceramic fiber prepared therefrom for heat insulating material at high temperature
ES2702108T3 (en) 2010-11-16 2019-02-27 Unifrax I Llc Inorganic fiber
CN113415998A (en) 2013-03-15 2021-09-21 尤尼弗瑞克斯 I 有限责任公司 Inorganic fiber
US10023491B2 (en) 2014-07-16 2018-07-17 Unifrax I Llc Inorganic fiber
JP6559219B2 (en) * 2014-07-16 2019-08-14 ユニフラックス ワン リミテッド ライアビリティ カンパニー Inorganic fiber with improved shrinkage and strength
US9556063B2 (en) 2014-07-17 2017-01-31 Unifrax I Llc Inorganic fiber with improved shrinkage and strength
US9919957B2 (en) 2016-01-19 2018-03-20 Unifrax I Llc Inorganic fiber
US11013836B2 (en) * 2016-06-16 2021-05-25 The Curators Of The University Of Missouri Inorganic biodegradable substrates for devices and systems
MX2020003641A (en) 2017-10-10 2020-07-29 Unifrax I Llc Crystalline silica free low biopersistence inorganic fiber.
US10882779B2 (en) 2018-05-25 2021-01-05 Unifrax I Llc Inorganic fiber

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052988A (en) * 1976-01-12 1977-10-11 Ethicon, Inc. Synthetic absorbable surgical devices of poly-dioxanone
US4140678A (en) * 1977-06-13 1979-02-20 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4141087A (en) * 1977-01-19 1979-02-27 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4155124A (en) * 1975-01-31 1979-05-22 Kyoto Ceramic Co., Ltd. Burnt ceramic bone implant
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4308064A (en) * 1978-10-19 1981-12-29 Ngk Spark Plugs Co., Ltd. Phosphate of calcium ceramics
US4329743A (en) * 1979-04-27 1982-05-18 College Of Medicine And Dentistry Of New Jersey Bio-absorbable composite tissue scaffold
US4411027A (en) * 1979-04-27 1983-10-25 University Of Medicine And Dentistry Of New Jersey Bio-absorbable composite tissue scaffold

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218355A (en) * 1978-07-21 1980-08-19 Ppg Industries, Inc. Low organic solvent-containing polyester coating compositions
JPS5576644A (en) * 1978-12-04 1980-06-09 Kyoto Ceramic Flexible ceramic living body inplant portion material
JPS5645814A (en) * 1979-09-25 1981-04-25 Kureha Chem Ind Co Ltd Hydroxyapatite, its ceramic material and its manufacture
JPS57117621A (en) * 1981-01-10 1982-07-22 Mitsubishi Mining & Cement Co Ltd Inorganic fiber of calcium phosphate and an implant material utilizing its properties
GB2099702B (en) * 1981-06-04 1984-08-08 Standard Telephones Cables Ltd Water-soluble prosthesis
JPS584821A (en) * 1981-07-02 1983-01-12 Mitsubishi Mining & Cement Co Ltd Production of calcium phosphate fiber
JPS6017118A (en) * 1983-07-06 1985-01-29 Mitsubishi Mining & Cement Co Ltd Calcium phosphate fiber
US4655777A (en) * 1983-12-19 1987-04-07 Southern Research Institute Method of producing biodegradable prosthesis and products therefrom
JPS61135671A (en) * 1984-12-04 1986-06-23 三菱鉱業セメント株式会社 Implant material

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155124A (en) * 1975-01-31 1979-05-22 Kyoto Ceramic Co., Ltd. Burnt ceramic bone implant
US4052988A (en) * 1976-01-12 1977-10-11 Ethicon, Inc. Synthetic absorbable surgical devices of poly-dioxanone
US4218255A (en) * 1976-08-30 1980-08-19 University Of Dayton Porous ceramic carriers for controlled release of proteins, polypeptide hormones, and other substances within human and/or other mamillian species and method
US4141087A (en) * 1977-01-19 1979-02-27 Ethicon, Inc. Isomorphic copolyoxalates and sutures thereof
US4140678A (en) * 1977-06-13 1979-02-20 Ethicon, Inc. Synthetic absorbable surgical devices of poly(alkylene oxalates)
US4308064A (en) * 1978-10-19 1981-12-29 Ngk Spark Plugs Co., Ltd. Phosphate of calcium ceramics
US4329743A (en) * 1979-04-27 1982-05-18 College Of Medicine And Dentistry Of New Jersey Bio-absorbable composite tissue scaffold
US4411027A (en) * 1979-04-27 1983-10-25 University Of Medicine And Dentistry Of New Jersey Bio-absorbable composite tissue scaffold

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0211942A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268463A3 (en) * 1986-11-19 1990-05-09 University Of Dayton Zinc based ceramics
EP0268463A2 (en) * 1986-11-19 1988-05-25 The University Of Dayton Zinc based ceramics
EP0271236A1 (en) * 1986-11-25 1988-06-15 The University Of Dayton Controlled pore size ceramics particularly for orthopaedic and dental applications
US5994247A (en) * 1992-01-17 1999-11-30 The Morgan Crucible Company Plc Saline soluble inorganic fibres
US6180546B1 (en) 1992-01-17 2001-01-30 The Morgan Crucible Company Plc Saline soluble inorganic fibers
EP0591696A1 (en) * 1992-10-09 1994-04-13 Nikon Corporation Bone grafting material
US5429996A (en) * 1992-10-09 1995-07-04 Nikon Corporation Bone grafting material
US5998315A (en) * 1994-08-02 1999-12-07 Morgan Crucible Company Plc Strontium aluminate inorganic fibers
US5928975A (en) * 1995-09-21 1999-07-27 The Morgan Crucible Company,Plc Saline soluble inorganic fibers
WO1998054104A1 (en) * 1997-05-31 1998-12-03 Giltech Limited Method of producing water-soluble glass fibres
WO2003059835A1 (en) 2002-01-04 2003-07-24 The Morgan Crucible Company Plc Saline soluble inorganic fibres
US8899981B2 (en) 2005-08-30 2014-12-02 Zimmer Dental, Inc. Dental implant for a jaw with reduced bone volume and improved osseointegration features
US10070945B2 (en) 2005-08-30 2018-09-11 Zimmer Dental, Inc. Dental implant for a jaw with reduced bone volume and improved osseointegration features
US8163377B2 (en) 2005-11-10 2012-04-24 The Morgan Crucible Company Plc High temperature resistant fibres
WO2008065363A1 (en) 2006-11-28 2008-06-05 The Morgan Crucible Company Plc Inorganic fibre compositions
US8088701B2 (en) 2006-11-28 2012-01-03 The Morgan Crucible Company Plc Inorganic fibre compositions
US9149345B2 (en) 2007-08-30 2015-10-06 Zimmer Dental, Inc. Multiple root implant
EP2213634A1 (en) 2007-11-23 2010-08-04 The Morgan Crucible Company Plc Inorganic fibre compositions
US9095396B2 (en) 2008-07-02 2015-08-04 Zimmer Dental, Inc. Porous implant with non-porous threads

Also Published As

Publication number Publication date
JPH075335B2 (en) 1995-01-25
AU5518386A (en) 1986-09-10
EP0211942A4 (en) 1987-11-23
US4604097B1 (en) 1991-09-10
EP0211942A1 (en) 1987-03-04
JPS62501905A (en) 1987-07-30
US4604097A (en) 1986-08-05

Similar Documents

Publication Publication Date Title
US4604097A (en) Bioabsorbable glass fibers for use in the reinforcement of bioabsorbable polymers for bone fixation devices and artificial ligaments
Xu et al. Calcium phosphate cement containing resorbable fibers for short-term reinforcement and macroporosity
Hench et al. Direct chemical bond of bioactive glass‐ceramic materials to bone and muscle
Franks et al. Development of soluble glasses for biomedical use Part I: In vitro solubility measurement
AU2007265379B2 (en) Bioactive bone graft substitute
Hench et al. Bonding mechanisms at the interface of ceramic prosthetic materials
CN103957951B (en) Composition and its purposes in knitting
EP0289562B1 (en) Surgical biocomposite material and a method for producing the material
BRPI1013728B1 (en) BIOCOMPATIBLE AND RESORBIBLE GLASS FIBER COMPOSITIONS AND THEIR USES
NL8503340A (en) IMPLANT MATERIAL FOR REPLACING HARD TISSUE OF THE LIVING BODY.
Dewi et al. Behavior of plaster of Paris‐calcium carbonate composite as bone substitute. A study in rats
Sukegawa et al. Feasible advantage of bioactive/bioresorbable devices made of forged composites of hydroxyapatite particles and poly-L-lactide in alveolar bone augmentation: A preliminary study
Furukawa et al. Bone Bonding Ability of a New Biodegradable Composite for Internal Fixation of Bone Fractures.
Moon et al. Bone formation in calvarial defects of Sprague‐Dawley rats by transplantation of calcium phosphate glass
Al-Haidary et al. Effect of yttria addition on mechanical, physical and biological properties of bioactive MgO–CaO–SiO2–P2O5–CaF2 glass ceramic
Hamson et al. Preliminary experience with a novel model assessing in vivo mechanical strength of bone grafts and substitute materials
Moon et al. Effect of calcium phosphate glass on bone formation in calvarial defects of Sprague-Dawley rats
Schendel et al. Preliminary report: a ceramic containing crosslinked collagen as a new cranial onlay and inlay material
Wu et al. Enhancement of biodegradation and osseointegration of poly (ε-caprolactone)/calcium phosphate ceramic composite screws for osteofixation using calcium sulfate
Eitenmuller et al. New Semi-Rigid and Absorbable Osteosynthesis Devices with a High Molecular Weight Polylactide (An Experimental Investigation
Zaffe et al. Study on short-term implants of a fluorinated glass in bone
Zhou et al. Biocompatibility in-vivo of poly-L-lactide and bioactive glass composite substitute for internal fracture fixation
McConaghy et al. Comparing the Rate of Dissolution of Two Commercially Available Synthetic Bone Graft Substitutes
Fernandes et al. Bonelike® Graft for Regenerative Bone Applications
Kontio Reconstruction of Orbital Wall Fracture: An experimental and clinical study

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR JP SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986901605

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986901605

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986901605

Country of ref document: EP